Cancer Research Horizons, the innovation arm of Cancer Research UK, is partnering with Diamond Light Source, the UK’s national synchrotron, to build a world-leading fragment-based drug discovery programme.
Diamond Light Source accelerates electrons to near light speed, producing bright light that is directed into research instruments known as beamlines. Cancer Research Horizons and its drug discovery site at Newcastle University have already been using Diamond’s beamlines and XChem facility for fragment-based screening, a powerful approach to identify chemical entities that can be developed…
Cambridge, UK: o2h discovery is pleased to announce the launch of o2h Biology Match Funding award, a unique programme aimed at accelerating drug discovery research by offering to match fund 50% of the cost for biology research projects up to $65K/£50K in value. This initiative presents an exciting opportunity for biotechs of all sizes and pharma to achieve key scientific milestones, helping to advance their drug discovery programmes.The o2h Biology Match Funding programme not only supports your biology project by matching up to 50% cost but also enables participants to tap into o2h’s vast…
03 December 2024, London - A message from Dr Rich Ferrie – CEO, LBIC
LBIC is evolving. A lot has changed since we opened as London’s first bio-incubator over 24 years ago.
Today, we’re at a pivotal moment in our history, entering a new phase of growth as we expand into the Apex Building and continue to evolve within the dynamic life sciences landscape.
As part of this evolution, we’re excited to reveal our refreshed brand identity, doubling down our short-form name ‘LBIC,’ which has been widely recognised across the sector for years. Our fresh new look reflects the energy and growth of our…
As 2024 draws to a close, Biocair, an established global leader in life sciences logistics, renews its commitment to its customers and looks forward to another busy year in 2025. Welcoming a new CEO refreshed the company’s customer focus, driving its continued efforts to tackle complex logistics challenges. The company has since made several strategic expansions to better deliver this expertise to the life sciences industry. Industry veteran guides next stage of growth Biocair started the year with the exciting announcement of its new CEO. Vincent Howard has been a part of the…
London, December 3, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Curve Therapeutics (“Curve”) and is pleased to announce the placement of Rab Prinjha, PhD, as Chief Research and Development (R&D) Officer.Curve Therapeutics is a private biotechnology company pioneering a revolutionary mammalian cell-based, functional drug discovery platform to address intracellular disease targets. Its mission is to improve patient outcomes by discovering…
London, United Kingdom, 29th November 2024 / One Nucleus
The 24th Life Science networking conference, organised by membership organisation One Nucleus, will be hosted at the Royal Society of Medicine, on Wednesday 4th December.
In a ‘first’ this year, Genesis is being co-located with Life Science Nation’s annual ‘Redefining Early-Stage Investments’ conference, connecting companies developing drugs, devices, digital health and diagnostic products with a global network of capital investors and licensing partners.
Delegates can register separately for both events, taking advantage…
The first half of 2024 has been an active year for M&A’s in the life sciences industry. The overall data reflects significant quarterly fluctuations in the total value and count of M&A deals within the life sciences sector from 2022 to mid-2024, highlighting shifting market priorities and potential external influences such as regulatory changes or macroeconomic factors.
For detailed information and statistics on the latest M&A activity in the biotechnology and digital health sectors, read the Life Sciences M&A Report. Published biannually by Venture Valuation, the report is…
The last People Pathways newsletter of 2024 is available to read now! You have the chance to be one of the first to secure a place on our 2025 courses and be part of the excellent pool of delegates we have already trained.Any queries, please email the team on training@onenucleus.com
New report reveals how groundbreaking research at the Campus is delivering major gains for UK economic growth and job creation
Cambridge, UK, 28th November 2024: A new independent report evaluating the economic and scientific impact of the Babraham Research Campus has revealed significant contributions not only to the UK and global life sciences sector, but to the local Cambridge and wider UK economy.
The independent evaluation, carried out between late 2023 and early 2024 by a team headed up by Professor Pete Tyler and Dr Andy Cosh, updates the findings from 2019 and captures a period…
4 December | 1 Wimpole Street, London
Will you be there for this unique opportunity to discuss the trends, best practice and future expectations of the Life Science sector? On Wednesday 4 December 2024, Genesis will assemble 300 life science influencers and integrate with the inaugural RESI London event to increase the opportunities to connect innovation, innovators and investors. See which companies are attending Genesis alone.
How will the Industry Evolve in 2025?The Keynote programme is packed with those driving business…